• Bots deliver time back to pharmacists

    Drones, robots and automated technologies are increasingly deployed across the healthcare landscape to speed workflows and improve efficiency. For pharmacists, amid a nationwide staffing shortage, tech is allowing them to work at the top of their license and serve more patients.
  • How does your system manage rare disease patients? Becker's wants to hear.

    Fill out this short survey here and attend our annual meeting for free.
  • Mallinckrodt emerges from bankruptcy

    Three years after Mallinckrodt filed for Chapter 11 bankruptcy, the Dublin-based drugmaker said Nov. 14 it has stabilized its business. 
  • Ambulatory pharmacies: A plethora of problems and opportunities

    Pittsburgh-based UPMC's Center for Connected Medicine teamed up with KLAS Research to survey 25 health system pharmacy leaders whose systems operate an average of seven ambulatory pharmacies each. 
  • Novo Nordisk shrinks insulin output

    Denmark-based Novo Nordisk is limiting its supply of insulin products, according to the American Society of Health-System Pharmacists' drug shortage database. 
  • Accord resumes making cancer drug cisplatin

    A year after the FDA found shredded quality documents at an Intas Pharmaceuticals drug manufacturing facility in India, Intas' parent company Accord Healthcare resumed making cisplatin, which has been in dire shortage for months.
  • Express Scripts follows Mark Cuban's lead on drug pricing

    The nation's second-largest pharmacy benefit manager, Express Scripts, is leaning into Mark Cuban Cost Plus Drugs' business plan by selling drugs priced by their acquisition cost, pharmacy dispensing and service costs.
  • CarelonRx: How pharmacists can provide high-quality care during a busy holiday season

    We're all often guilty of it. Being so busy that we begin to rush. I often need to take a figurative and literal breath to remember why I – and I'm sure many of us – became pharmacists in the first place: to help people lead healthier lives.
  • Experimental gene therapy halves cholesterol in small study

    Boston-based Verve Therapeutics presented strong findings Nov. 12 for a gene therapy candidate aimed at disabling the gene linked to low-density lipoprotein cholesterol. 
  • Novo Nordisk to bolster manufacturing capacity of weight loss drugs

    Novo Nordisk will invest more than $6 billion to expand manufacturing facilities in Denmark, the company said Nov. 10. The facility will support increased production capacity for its GLP-1 drugs Ozempic and Wegovy, and other chronic disease treatments. 
  • 'This will change prescribing practices': Wegovy cuts risk of major heart events in large study

    Long-awaited findings from an international study of more than 17,000 patients showed the weight loss drug Wegovy reduced the risk of having a heart attack or stroke, and the risk of dying from a heart attack.
  • A shortage of hospital pharmacists is on the horizon, leaders say

    As applications for pharmacy schools and residency programs wither, hospital pharmacy leaders are warily preparing for a shortage of clinical pharmacists. 
  • Health systems plunge into home infusion service lines

    Despite financial headwinds, the healthcare industry is plugging money and resources into home infusion service lines, according to Provident Healthcare Partners.
  • FDA approves 1st Chikungunya virus vaccine

    The FDA on Nov. 9 granted approval to Ixchiq, the first vaccine to protect against chikungunya virus. 
  • Walgreens chief medical officer exits

    The chief medical officer of Walgreens Boots Alliance, Kevin Ban, MD, will exit his role as of Nov. 10, a spokesperson confirmed to Becker's.
  • Walgreens to lay off 5% of corporate staff

    Walgreens is planning to lay off about 5% of its corporate workforce, or 267 employees, the Chicago Tribune reported Nov. 9.
  • 5 growth areas for health system pharmacy leaders: McKinsey

    Hospital and health system pharmacy leaders might be missing out on big-picture goals in "emerging frontiers" as they extinguish long-standing issues, such as rising healthcare costs and a pharmacy technician shortage, according to an Oct. 7 article from McKinsey. 
  • Postpartum depression drug may cost some nearly $16K out of pocket

    Shelling out nearly $16,000 for a 14-day course of medication is what to expect for the wholesale cost of Zurzuvae, the first oral treatment for postpartum depression, according to a Nov. 7 news release from drugmaker Sage Therapeutics. 
  • Retail pharmacy walkout organizers push for unionization

    After a three-day walkout of retail pharmacy employees across the U.S., organizers of the grassroots labor action created an organization that seeks to unionize the workforce and advocate for safer working conditions. 
  • Cancer drugs: 4 things to know

    As 2023 entered its fourth quarter, one cancer drug shortage resolved as more than a dozen continue; a California system helped make a chemotherapy management app; and the FDA approved a new head and neck cancer medication. 
  • FDA approves new weight loss drug

    On Nov. 8, the FDA approved Eli Lilly's Zepbound (tirzepatide), a weekly injection for chronic weight management. 

Featured Whitepapers

Featured Webinars